CNS Pharmaceuticals Inc. CNSP Archives - Page 15 of 22

WednesdayJul 21, 2021 9:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Begin Patient Dosing in Berubicin Phase 2 Clinical Trial During Q3 2021, and Received Fast Track Designation from FDA

CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the…

MondayJul 12, 2021 10:27 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to interact more frequently with the FDA for the purposes of expediting the development and review process; the designation is reserved for drugs with the potential to address unmet medical need in the treatment of serious or life-threatening…

ThursdayJul 01, 2021 12:53 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued progress to drive Berubicin towards commercialization for the treatment of glioblastoma multiforme (“GBM”). “In the last 60 days alone, we have achieved fundamental clinical, regulatory and corporate milestones that together demonstrate CNS’ operational, strategic and financial strengths. We are continuously de-risking our Berubicin clinical program by driving development of this truly novel treatment forward as expeditiously as possible. In a…

TuesdayJun 29, 2021 11:13 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). An anthracycline, Berubicin falls in a class of anticancer agents that are among the most powerful chemotherapy drugs, proven to be effective against more types of cancer than any other category of chemotherapeutic agents. Fast…

MondayJun 28, 2021 3:37 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), WPD Pharmaceuticals to Soon Recruit Patients for Combined Berubicin Clinical Studies

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30 countries mainly in Europe and Asia. WPD, a clinical-stage pharmaceutical company, today provided an update on its Berubicin drug candidate clinical development program for the treatment of glioblastoma multiforme (“GBM”). According to the update, WPD plans to commence its Phase Ib/II Study of Berubicin in the treatment of glioblastoma in the second half of 2021. In addition, CNS Pharmaceuticals has announced open enrollment in the…

TuesdayJun 22, 2021 1:39 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin in the treatment of several serious brain and central nervous system oncological indications. CNS is set to commence patient enrollment in a potentially pivotal study to evaluate the efficacy of Berubicin for adult glioblastoma multiforme (“GBM”) in the second quarter. Additionally, its sublicensee partner in Poland, WPD Pharmaceuticals, will initiate a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients and is also…

MondayJun 21, 2021 12:08 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances

Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventions One patient from the Phase 1 trial of Berubicin 15 years ago remains cancer-free, as assessed in November, despite glioblastoma’s reputation for proving fatal generally within about 15 months of diagnosis CNS recently announced it will be included…

FridayJun 18, 2021 2:22 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reports First Quarter Financials; Anticipates Improved Patient Outcomes with Berubicin

Company expects reporting on interim analysis for the first 18 patients of a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients during the first half of 2022 One patient from the first Berubicin trial has survived cancer-free for 14 years, while two patients saw tumor reduction of up to 80 percent CNS Pharmaceuticals reported a net loss of $3.6 million, attributed to increased personnel, activity preparing for clinical trials, drug manufacturing, and labor for the Phase 2 study The global brain tumor therapeutics market is expected to grow at a CAGR during 2020-2025, resulting in forecasted market…

ThursdayJun 17, 2021 12:44 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set for Inclusion in Russell 2000 Index

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the Russell 2000(R) Index, effective June 25, 2021, after the close of the U.S. equity markets. CNSP will be added following the annual reconstitution of the Russell stock indexes. According to the announcement, the Russell 2000 Index, which is a subset of the Russell 3000(R) Index, measures the performance of the small-cap segment of the equity market in the United States and includes an estimated 2,000…

WednesdayJun 02, 2021 1:38 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that is nearly 100% fatal in patients just over a year after diagnosis. CNS Pharmaceuticals’ lead drug candidate, Berubicin, has been granted investigational new drug (“IND”) status after promising findings. “Berubicin is a standout anthracycline therapy because of its novel apparent ability to cross the blood-brain barrier to combat neurological tumors. The drug was the subject of a Phase I trial some 15 years ago in…

Site Search

Company Search

Tag: CNS Pharmaceuticals Inc. CNSP